Back Back
Cell No. : Cell Name
RCB1551 : JHUEM-2  update : 2024/04/03
CommentHuman cell line derived from uterine endometrioid adenocarcinoma. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Contact Us
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.ISHIKAWA Hiroshi (Cell Bank)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M. & Yamada, K.
Year of deposit 1999
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 62 years
Tissue uterus
Disease name Endometrioid adenocarcinoma
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_4656
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 49(50)
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 10

To topTop

To topTop
User's Publication
21247  Subbiah V, Sahai V, Maglic D, Bruderek K, Toure BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schonherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB.  RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations.  Cancer Discov  2023    PubMed ID: 37270847   DOI: 10.1158/2159-8290.CD-23-0475
18230  Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J.  Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line  Sci Rep  2022  12(1):19731.  PubMed ID: 36396974   DOI: 10.1038/s41598-022-24211-8
4046  Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, Kohno T.  Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers  Cancer Cell  2019  35(2):177-190  PubMed ID: 30686770   DOI: 10.1016/j.ccell.2018.12.009
11270  Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M.  VISTA expressed in tumour cells regulates T cell function.  Br. J. Cancer  2019    PubMed ID: 30382166   DOI: 10.1038/s41416-018-0313-5
11333  Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.  Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.  Mol Oncol  2019    PubMed ID: 30537101   DOI: 10.1002/1878-0261.12422
10231  Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.  PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.  Mol. Cancer Ther.  2017  16:637-648  PubMed ID: 28119489   DOI: 10.1158/1535-7163.MCT-16-0415
4393  Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.  The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.  Neoplasia  2013  15(8):975-88  PubMed ID: 23908597   DOI: 10.1593/neo.121106
8749  Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, Ito K, Suzuki T, Sasano H, Yaegashi N, Hayashi S.  Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction.  Endocr. Relat. Cancer  2008  15:451-63  PubMed ID: 18508998   DOI: 10.1677/ERC-07-0227
8772  Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.  Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.  Kobe J Med Sci  2007  53:177-87  PubMed ID: 18204294  
3796  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956   DOI: 10.1002/ijc.11348

Back Back Return Top Page